Strategies for managing chemotherapy-induced sensory neuropathy

Joleen M Hubbard, Axel F Grothey

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced sensory neuropathy occurs in most patients undergoing treatment with oxaliplatin for colorectal cancer. Although the acute form of neurotoxicity is transient, the chronic form, which is correlated with the cumulative dose of oxaliplatin administered over time, may be long lasting in a subset of patients and may have a significant impact on function and quality of life. Because treatment options for established chemotherapy-induced peripheral neuropathy are limited, recent efforts have focused on prevention. This review discusses acute and chronic neurotoxic effects of oxaliplatin, the most recent evidence for decreasing the probability of developing peripheral neuropathy, and the clinical management of existing neuropathy.

Original languageEnglish (US)
Pages (from-to)126-132
Number of pages7
JournalCurrent Colorectal Cancer Reports
Volume6
Issue number3
DOIs
StatePublished - Jul 2010

Fingerprint

oxaliplatin
Peripheral Nervous System Diseases
Drug Therapy
Colorectal Neoplasms
Quality of Life
Therapeutics

Keywords

  • Colorectal cancer
  • FOLFOX
  • Neuromodulatory agents
  • Neuropathy
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Strategies for managing chemotherapy-induced sensory neuropathy. / Hubbard, Joleen M; Grothey, Axel F.

In: Current Colorectal Cancer Reports, Vol. 6, No. 3, 07.2010, p. 126-132.

Research output: Contribution to journalArticle

@article{fd69f90802ef4acf85560814dcf1e009,
title = "Strategies for managing chemotherapy-induced sensory neuropathy",
abstract = "Chemotherapy-induced sensory neuropathy occurs in most patients undergoing treatment with oxaliplatin for colorectal cancer. Although the acute form of neurotoxicity is transient, the chronic form, which is correlated with the cumulative dose of oxaliplatin administered over time, may be long lasting in a subset of patients and may have a significant impact on function and quality of life. Because treatment options for established chemotherapy-induced peripheral neuropathy are limited, recent efforts have focused on prevention. This review discusses acute and chronic neurotoxic effects of oxaliplatin, the most recent evidence for decreasing the probability of developing peripheral neuropathy, and the clinical management of existing neuropathy.",
keywords = "Colorectal cancer, FOLFOX, Neuromodulatory agents, Neuropathy, Oxaliplatin",
author = "Hubbard, {Joleen M} and Grothey, {Axel F}",
year = "2010",
month = "7",
doi = "10.1007/s11888-010-0055-0",
language = "English (US)",
volume = "6",
pages = "126--132",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Strategies for managing chemotherapy-induced sensory neuropathy

AU - Hubbard, Joleen M

AU - Grothey, Axel F

PY - 2010/7

Y1 - 2010/7

N2 - Chemotherapy-induced sensory neuropathy occurs in most patients undergoing treatment with oxaliplatin for colorectal cancer. Although the acute form of neurotoxicity is transient, the chronic form, which is correlated with the cumulative dose of oxaliplatin administered over time, may be long lasting in a subset of patients and may have a significant impact on function and quality of life. Because treatment options for established chemotherapy-induced peripheral neuropathy are limited, recent efforts have focused on prevention. This review discusses acute and chronic neurotoxic effects of oxaliplatin, the most recent evidence for decreasing the probability of developing peripheral neuropathy, and the clinical management of existing neuropathy.

AB - Chemotherapy-induced sensory neuropathy occurs in most patients undergoing treatment with oxaliplatin for colorectal cancer. Although the acute form of neurotoxicity is transient, the chronic form, which is correlated with the cumulative dose of oxaliplatin administered over time, may be long lasting in a subset of patients and may have a significant impact on function and quality of life. Because treatment options for established chemotherapy-induced peripheral neuropathy are limited, recent efforts have focused on prevention. This review discusses acute and chronic neurotoxic effects of oxaliplatin, the most recent evidence for decreasing the probability of developing peripheral neuropathy, and the clinical management of existing neuropathy.

KW - Colorectal cancer

KW - FOLFOX

KW - Neuromodulatory agents

KW - Neuropathy

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=79952735457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952735457&partnerID=8YFLogxK

U2 - 10.1007/s11888-010-0055-0

DO - 10.1007/s11888-010-0055-0

M3 - Article

VL - 6

SP - 126

EP - 132

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -